Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 1.00 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.69 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | APP | P05067 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.63 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.63 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
| ▸ | BCR | P11274 | 1/20 | 0.57 |
| ▸ | PRKCA | P17252 | 1/20 | 0.57 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | RXRB | P28702 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.53 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.53 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28297133 | 1.00 | KMO (1.00) | KMOMKNK1MKNK2ALDH1A1APP | |
| SCHEMBL29569537 | 1.00 | KMO (1.00) | KMOMKNK1MKNK2ALDH1A1APP | |
| SCHEMBL28790987 | 0.88 | KMO (0.79) | KMOMKNK1MKNK2ALDH1A1APP | |
| SCHEMBL17089048 | 0.87 | KMO (0.77) | KMOMKNK1MKNK2ALDH1A1APP | |
| SCHEMBL10028699 | 0.87 | KMO (0.77) | KMOMKNK1MKNK2ALDH1A1APP | |
| SCHEMBL29503876 | 0.87 | KMO (0.77) | KMOMKNK1MKNK2ALDH1A1APP | |
| SCHEMBL27605046 | 0.87 | KMO (0.77) | KMOMKNK1MKNK2ALDH1A1APP | |
| SCHEMBL16109362 | 0.86 | KMO (0.76) | KMOMKNK1MKNK2ALDH1A1APP | |
| SCHEMBL1690466 | 0.86 | KMO (0.75) | KMOMKNK1MKNK2ALDH1A1APP | |
| SCHEMBL29911642 | 0.85 | KMO (0.74) | KMOMKNK1MKNK2GAARXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-109824028-A | It is a kind of using coordination polymer as the nitrogen-doped porous carbon material of precursor preparation and application | 华南师范大学 | 2019-05-31 | — | — | CN | claimed |
| US-20260027106-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2026-01-29 | — | — | US | disclosed |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | KAINOS MEDICINE, INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| EP-4603488-A1 | NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea University Research and Business Foundation (KR) | 2025-08-20 | — | — | EP | disclosed |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-08-05 | — | — | US | disclosed |
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024080780-A1 | NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 고려대학교 산학협력단 | 2024-04-18 | — | — | WO | disclosed |
| CN-116940562-A | Acetamido-phenylbenzamide derivatives and methods of use thereof | 希华医药有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4225745-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Athenex, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-1663204-A2 | C-KIT MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1660507-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2006055553-A2 | NOVEL M3 MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-05-26 | — | — | WO | disclosed |
| WO-2006010082-A1 | 1,4-DISUBSTITUTED NAPHTALENES AS INHIBITORS OF P38 MAP KINASE | ARQULE, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
| WO-2005021558-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005020921-A2 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| EP-1480954-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027106-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT3 | KMO 1505/4885MKNK1 1752/4885MKNK2 1293/4885 |
| US-12378224-B2 | Heteroaryl compounds and their use as Mer inhibitors | MERTK, RET, ERBB2 | KMO 2022/4885MKNK1 831/4885MKNK2 658/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | KMO 3770/4885MKNK1 715/4885MKNK2 933/4885 |
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | KMO 2512/4885MKNK1 46/4885MKNK2 49/4885 |
| US-12534452-B2 | N-(1H-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient | IRAK4, IRAK1, IRAK2 | KMO 1461/4885MKNK1 2469/4885MKNK2 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.